Figure 6.
Pharmacological inhibition of PRL2 reduces leukemia burden and extends the survival of mice transplanted with primary human AML cells. (E) Kaplan-Meier survival curve of NSG mice transplanted with 4 × 106 human CD45+ leukemia cells (AML3179) following 3 weeks of DMSO or PRLi treatment (n = 6 mice per group).

Pharmacological inhibition of PRL2 reduces leukemia burden and extends the survival of mice transplanted with primary human AML cells. (E) Kaplan-Meier survival curve of NSG mice transplanted with 4 × 106 human CD45+ leukemia cells (AML3179) following 3 weeks of DMSO or PRLi treatment (n = 6 mice per group).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal